
Violeta Sanchez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/784754/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. Cell Metabolism, 2017, 26, 633-647.e7.	16.2	449
2	Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets. Cancer Discovery, 2014, 4, 232-245.	9.4	413
3	DNA methyltransferase inhibition upregulates MHC-l to potentiate cytotoxic T lymphocyte responses in breast cancer. Nature Communications, 2018, 9, 248.	12.8	181
4	Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Research, 2017, 77, 2488-2499.	0.9	178
5	A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nature Medicine, 2019, 25, 1243-1250.	30.7	133
6	Genomic profiling of ER ⁺ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Science Translational Medicine, 2017, 9, .	12.4	91
7	Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer. Cancer Research, 2017, 77, 3280-3292.	0.9	76
8	Rictor/mTORC2 Drives Progression and Therapeutic Resistance of <i>HER2</i> -Amplified Breast Cancers. Cancer Research, 2016, 76, 4752-4764.	0.9	71
9	Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1. Cancer Research, 2019, 79, 171-182.	0.9	57
10	Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis. Breast Cancer Research, 2017, 19, 74.	5.0	55
11	Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. Cancer Research, 2018, 78, 1845-1858.	0.9	54
12	Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. Oncolmmunology, 2018, 7, e1438106.	4.6	54
13	Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors. Science Translational Medicine, 2020, 12, .	12.4	46
14	Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade. Molecular Cancer Research, 2017, 15, 259-268.	3.4	40
15	Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer. Clinical Cancer Research, 2021, 27, 5299-5306.	7.0	39
16	Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. Clinical Cancer Research, 2020, 26, 5668-5681.	7.0	37
17	Quantitative [18F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer. Molecular Imaging and Biology, 2017, 19, 130-137.	2.6	24
18	ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation. Breast Cancer Research, 2017, 19, 105.	5.0	23

VIOLETA SANCHEZ

#	Article	IF	CITATIONS
19	Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers. Oncotarget, 2019, 10, 5389-5402.	1.8	18
20	Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death and Disease, 2018, 9, 21.	6.3	16
21	Tissue-specific expression of p73 and p63 isoforms in human tissues. Cell Death and Disease, 2021, 12, 745.	6.3	13
22	ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. Oncotarget, 2015, 6, 22348-22360.	1.8	12
23	Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones. Journal of Clinical Investigation, 2021, 131, .	8.2	11
24	Abstract PS17-14: Evaluating the efficacy of immunotherapy in triple negative breast cancer. , 2021, , .		0
25	Abstract PS4-19: Evaluation of tumor-specific MHC-II expression as a biomarker. , 2021, , .		0
26	245â€Host myeloid response to tumor and immunotherapy is associated with heterogeneity in outcomes to anti-PDL1. , 2021, 9, A264-A264.		0